Apellis Pharmaceuticals, Inc. (APLS)

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase...

Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript...

Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript...

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conf...

Connor Clark and Lunn Investment Management Ltd. lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) by 10.0% in the undefined quarter, according to its most recent filing ...

Apellis Pharmaceuticals, Inc. ( APLS ) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President ...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continu...

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, Nove...

APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment....

Apellis Pharmaceuticals, Inc. ( APLS ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Eva Stroynowski Cedric Francois - Co-Founder, President, CEO & Director David Acheson - E...